Our results suggested integrin β3 might contribute a potential link between FAK signaling and CNSL in patients with T-ALL, supporting the hypothesis of FAK targeting therapeutic options, considering that 30%–40% of T-ALL relapses occur in the CNS [8]. The gene discussed is PTK2; the disease is acute lymphoblastic leukemia.